Biocom California’s Global Life Science Partnering & Investor Conference kicked off with a panel discussion focused on artificial intelligence (AI) in drug discovery. While there’s been a lot of hype over how AI and machine learning have the potential to help companies speed up drug development, panelists hypothesized the largest opportunities are in developing new capabilities, potentially increasing the success rate going from discovery to regulatory approval.
Following up on a 2021 partnership with Takeda Pharmaceutical Co. Ltd., Bridgene Biosciences Inc. has signed up a second international drug company, Galapagos NV, to use its chemoproteomic platform, IMTAC (Isobaric Mass Tagged Affinity Characterization), to discover small-molecule drug candidates.
Multiple studies at the 65th American Society of Hematology Annual Meeting 2023 have the potential to change the treatment paradigm for first-line treatment of multiple myeloma.
It’s not every day you see a small drug company’s presentations get picked for both the plenary session and the late-breaker session at a conference, but Syndax Pharmaceuticals Inc. managed to do just that at the 65th American Society of Hematology Annual Meeting 2023 – with a little help from a friend.
CAR T-cell therapies have worked well at curing blood malignancies, but a group out of the University Hospital of Erlangen have repurposed the technology as a treatment for autoimmune diseases. The expansion into new diseases has required cooperation between multiple departments, with CAR T experts taking the lead on treatment and potential side effects, and rheumatologists measuring the outcomes of the treatment.
Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those changes affect cells, but also looking to take advantage of the changes to create products in manufacturing processes that wouldn’t be possible on earth.
According to venture capitalists on three different panels at Biocom California’s Global Life Science Partnering & Investor Conference, there’s still money available for newcos looking to get started. But the pitch they’re going to have to make to VCs is a little different than what would have worked a few years ago.
During two different panels at Biocom California’s Global Life Science Partnering & Investor Conference, executives from a variety of pharmaceutical companies laid out their wants and needs in the current market environment. Large drug companies have relied on biotech companies to build out their pipelines for many years, but the level of outside inventions has been increasing over the last few years.
Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those changes affect cells, but also looking to take advantage of the changes to create products in manufacturing processes that wouldn’t be possible on earth.
Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those changes affect cells, but also looking to take advantage of the changes to create products in manufacturing processes that wouldn’t be possible on earth.
